Phytoestrogens exert pleiotropic effects on cellular signaling and show some beneficial effects on estrogen-dependent diseases. However, due to activation/inhibition of the estrogen receptors ERa or ERb, these compounds may induce or inhibit estrogen action and, therefore, have the potential to disrupt estrogen signaling. We performed a comprehensive analysis and potency comparison of phytoestrogens and their human metabolites for ER binding, induction/ suppression of ERa and ERb transactivation, and coactivator recruitment in human cells. The soy-derived genistein, coumestrol, and equol displayed a preference for transactivation of ERb compared to ERa and were 10-to 100-fold less potent than diethylstilbestrol. In contrast, zearalenone was the most potent phytoestrogen tested and activated preferentially ERa. All other phytoestrogens tested, including resveratrol and human metabolites of daidzein and enterolactone, were weak ER agonists. Interestingly, the daidzein metabolites 3 0 ,4 0 ,7-isoflavone and 4 0 ,6,7-isoflavone were superagonists on ERa and ERb. All phytoestrogens tested showed reduced potencies to activate ERa and ERb compared to diethylstilbestrol on the estrogen-responsive C3 promoter compared to a consensus estrogen response element indicating a degree of promoter dependency. Zearalenone and resveratrol were antagonistic on both ERa and ERb at high doses. The phytoestrogens enhanced preferentially recruitment of GRIP1 to ERa similar to 17b-estradiol. In contrast, for ERb no distinct preference for one coactivator (GRIP1 or SRC-1) was apparent and the overall coactivator association was less pronounced than for ERa. Due to their abundance and (anti)-estrogenic potencies, the soy-derived isoflavones, coumestrol, resveratrol, and zearalenone would appear to have the potential for effectively functioning as endocrine disruptors.
The estrogenic effects of a variety of structurally diverse plant-derived compounds are mediated through the estrogen receptors ERa and ERb, which function as ligand-inducible transcription factors for genes involved in cell growth, proliferation, and differentiation (Hall et al., 2001; Mueller and Korach, 2001b) . Due to activation of the ER, these compounds are referred to as phytoestrogens and have the potential to disrupt estrogenic signaling. In vitro studies indicated that ERa and ERb display marked differences in binding affinity and activation by some natural and synthetic ER ligands (Kuiper et al., 1997 (Kuiper et al., , 1998 . Interestingly, although ERb shows lower binding affinity for and activation by endogenous estrogens, some xenoestrogens preferentially bind and activate ERb (Kuiper et al., 1998) . Although epidemiological data indicated that several phytoestrogens like the soy isoflavones may have protective effects on estrogen-dependent malignancies (Adlercreutz, 1995) , data on disruption of ER function, adverse effects observed in rodents (Jefferson and Newbold, 2000) , and the eventually high doses of dietary phytoestrogens (Bingham et al., 1998) warrant a more thorough analysis of the potential dysregulation of ER action by phytoestrogens.
Most phytoestrogens exert pleiotropic effects involving kinase inhibition, cell cycle regulation, and antioxidative properties that are likely to contribute to the beneficial effects of phytoestrogens (Basly et al., 2000; Cappelletti et al., 2000) . Nevertheless, estrogenic and/or antiestrogenic activities of phytoestrogens like resveratrol and genistein may reduce but also stimulate estrogen-dependent tumor growth depending on dose and timing of exposure (Allred et al., 2001; Cotroneo et al., 2002) .
So, we have analyzed a selection of phytoestrogens ( Fig. 1) , with known or suspected estrogenic action (reviewed in Cassidy et al., 2000; Mazur and Adlercreutz, 2000; Mueller, 2002) , in a series of cellular assays for dose-dependent agonistic and antagonistic activity on ERa and ERb. One major drawback of cellular assays is that the cell lines used are incapable of metabolizing xenobiotics. Therefore, we have evaluated some of the major human metabolites of enterolactone and daidzein for their estrogenic activities ( Fig. 1 ; Niemeyer et al., 2000) . Several reports have been published that characterized selected features of phytoestrogen action including receptor binding, ER transactivation, or target gene expression (reviewed in Mueller, 2002) . However, a comprehensive analysis of the potencies of several phytoestrogens in one comparable system for both ERa and ERb activities is lacking. Thus, we have employed a human endometrial Ishikawa cell line that stably expresses human ERa or ERb (Mueller et al., 2003a) to assess the estrogenic and antiestrogenic potencies of the selected phytoestrogens (Fig. 1) . Furthermore, binding affinities for ERa and ERb were analyzed. To elucidate the mechanism of ER activation or inhibition by phytoestrogens in more detail, we evaluated the recruitment of coactivators to ERa and ERb by selected phytoestrogens in mammalian two-hybrid assays. By using this approach, we were able to rank and characterize the analyzed phytoestrogens for their estrogenic and/or antiestrogenic properties in human cells.
MATERIALS AND METHODS
Materials and biochemicals. Media, supplements, enzymes, and chemicals were purchased from Sigma Chemical Co. (St. Louis, MO). Steroid-deprived, dextran-coated, charcoal-treated fetal bovine serum (DCC/FBS) was from Hyclone (lot AKD11642A, Perbio Science, Bonn, Germany). ICI 182,780 (ICI) was from Tocris (Bristol, UK). Test compounds and phytoestrogens were purchased from Sigma Chemical Co. or Fluka Chemical Corp. (Ronkonkoma, NY) and were of the highest purity available. Enterolactone (ENL, purity 4 99%) and its human metabolite 6-hydroxy-enterolactone (6OH-ENL, purity 4 99%) were synthesized and purified as described previously Niemeyer et al., 2000) . The human daidzein metabolites 4 0 ,6,7-trihydroxy-isoflavone (467-IF, purity 98%) and 3 0 ,4 0 ,7-trihydroxyisoflavone (347-IF, purity 4 98%) were from Fluka Chemical Corp.
Cell culture. Human endometrial Ishikawa cells with stable expression of human ERa (Ishikawa-hERa) or human ERb (Ishikawa-hERb; Mueller et al., 2003a) were cultured in phenol red-free Dulbecco's modified Eagle medium (DMEM)/F12 supplemented with 10% DCC/FBS, as described previously (Mueller et al., 2003a) . Human hepatoma HepG2 cells were maintained in DMEM/F12 supplemented with 10% FBS, sodium pyruvate, and antibiotics. Cells were cultured at 37 C/5% CO 2 in air in a humidified atmosphere.
Ligand-binding studies by fluorescence polarization. Ligand-binding affinities to purified human ERa and ERb were determined by competition binding of the test compounds against fluorescein-labeled estradiol (ES2) using an ERscreening kit according to the manufacturer's protocol (Panvera, Göttingen, Germany). Recombinant human ERa or ERb (10 nM) were incubated with the test compounds for 2 h in the presence of 1 nM ES2 (Panvera). Fluorescence polarization was measured using a Polarion multiwell plate reader (Tecan, Crailsheim, Germany) . Ligand concentration yielding 50% inhibition of binding of fluorescently labeled ES2 to ER (IC 50 ) was derived by nonlinear curve-fitting using ORIGIN software (Microcal Software, Northhampton, MA) from competition binding curves. The IC 50 were determined from at least three independent experiments and are given as mean 6 standard deviation.
Transient transfection and transactivation assay. Ishikawa-hERa and Ishikawa-hERb cells were seeded on 24-well plates 15 h prior to transfection in phenol red-free DMEM/F12 supplemented with 10% DCC/FBS. The plasmids were transfected in phenol red-free DMEM/F12 supplemented with 5% DCC/FBS using Fugene 6 (Roche, Mannheim, Germany), according to the manufacturer's protocol. Each well received 0.5 mg of reporter plasmid and 0.01 mg pRL-CMV (Renilla luciferase for normalization; Promega, Madison, WI). A firefly luciferase reporter driven by three copies of the vitellogenin estrogen response element (3 3 ERE-Luc) and a reporter containing the human complement 3 gene (C3) promoter (reporter kindly provided by D. P. McDonnell, Duke University, Durham, NC) were used to measure ER transcriptional activity. Test compounds (final concentration of vehicle ethanol 1% v/v) in 200 ml phenol red-free DMEM/F12 supplemented with 10% DCC/FBS were added to the cells after transfection and incubated for 22 h. Luciferase assays were performed using Mammalian two-hybrid assays. For mammalian two-hybrid assays, HepG2 cells were plated in 24-well plates 15 h prior to transfection. The plasmids were transfected in phenol red-free DMEM/F12 supplemented with 5% DCC/ FBS using Fugene 6 (Roche), as described previously (Mueller et al., 2003a) . In standard transfections, 0.5 mg of reporter 5 3 -Gal4-TATA-Luc, containing five binding sites for the yeast Gal4 transcription factor, 0.09 mg of receptor (either pVP16-hERa [GenBank accession M12674] or pVP16-hERb [GenBank accession AF051427, ''short'' form of ERb]), 0.5 mg of Gal4 DNA binding domain fused to the nuclear receptor interaction domain (NR-box) of each coactivator (pM-SRC-1 [NR box] or pM-GRIP1 [NR box]; plasmids kindly provided by D. P. McDonnell), and 0.01 mg of the pRL-CMV Renilla luciferase normalization vector were used for each well. Test compounds in 200 ml phenol red-free DMEM/F12 supplemented with 10% DCC/FBS were then added to the cells and incubated for 22 h. Luciferase assays were performed using the dualluciferase reporter assay system according to the manufacturer's protocol. Each value was normalized to the Renilla luciferase control, and each data point generated is the average with range of duplicate determinations. All experiments were performed three times.
RESULTS

Phytoestrogens Showed Distinct Binding Affinities to Human ERa and ERb
Binding of a ligand to the ER is the first determinant for its potential to act as an ER agonist or antagonist. Therefore, we analyzed the binding affinities of the following phytoestrogens: coumestrol (COUM); the isoflavone genistein (GEN); the human daidzein metabolites equol, 4 0 ,6,7-trihydroxy-isoflavone (467-IF), and 3 0 ,4 0 ,7-trihydroxy-isoflavone (347-IF); the stilbene resveratrol (RESV); the resorcyclic acid lactone zearalenone (ZEA); and the lignans enterolactone (ENL) and its human metabolite 6-hydroxy-enterolactone (6OH-ENL; Fig. 1 ). Competition binding studies were performed with purified human ERa or ERb and fluorescein-labeled E2 (Mueller et al., 2003b) . A ranking of the relative binding affinities (RBA) confirmed that GEN, COUM, ZEA, and equol have the highest binding affinities to ERa and ERb and that GEN, COUM, and equol showed a distinct preference for ERb (Table 1 ; Kuiper et al., 1998; Mueller, 2002 ). The other phytoestrogens tested showed rather weak binding affinities compared to the potent synthetic estrogen diethylstilbestrol (DES) and the endogenous estrogen 17b-estradiol (E2; Table 1 ).
Phytoestrogens Exerted Distinct Agonistic and/or
Antagonistic Activity on Human ERa and ERb
Binding affinity to ER has been used frequently as a surrogate marker for estrogenicity. However, binding to the ER does not necessarily result in agonistic activity and may lead to antagonistic activity on ERa or ERb. Previously, we have performed transactivation assays in human endometrial Ishikawa cells that stably express human ERa (Ishikawa-hERa) or ERb (IshikawahERb; Mueller et al., 2003a) . The parental Ishikawa cells (IgnarTrowbridge et al., 1995) lack endogenously active ERa and ERb and the stably transfected cell lines offer the advantage of constitutive expression of either human ERa or ERb (Mueller et al., 2003a) . It is by now well established that the promoter sequence of estrogen target genes can determine the activity of liganded ER Klinge, 2001) . So, we analyzed the activity of phytoestrogens on a reporter with three copies of the vitellogenin A consensus ERE (3 3 ERE; Norris et al., 1997) and on the estrogen-responsive C3 promoter that contains several nonconsensus EREs (Norris et al., 1996) .
The dose-response transactivation curves of the tested phytoestrogens on the 3 3 ERE reporter are shown in Figure 2 . For comparison of the estrogenic potencies of phytoestrogens with that of DES and E2, we calculated the EC 50 values for ER transactivation. Also, the efficacy, i.e., the maximum-fold induction over control observed, was also determined (Fig. 3) . The overall ranking of the potency was consistent with the observed binding affinities (Table 1) . ZEA and COUM were the most potent phytoestrogens on ERa, and COUM, GEN, and equol preferentially activated ERb (Fig. 3 ) in accordance with published reports (reviewed in Mueller, 2002) . In contrast, ZEA had higher potencies on ERa than on ERb (Fig. 3 ). RESV and ENL showed very low potency to induce ERa or ERb activity; 6OH-ENL and the daidzein metabolites 347-IF and 467-IF displayed the lowest potencies to activate ERa or ERb (Fig. 3) . 
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Comparison of the activities on the consensus 3 3 ERE with the C3 promoter revealed that the potency of the phytoestrogens was in general lower on the C3 promoter (Fig. 3) ; however, the ranking was not affected with one exception. ZEA, rather potent to induce ERb activity on the 3 3 ERE, transactivated ERb only 2-fold compared to untreated control on the C3 promoter. Therefore, no EC 50 value could be calculated (Fig. 3C) .
Another measure of estrogenic activity is the efficacy. ZEA, COUM, GEN, equol, and RESV had efficacies that were comparable to DES and E2 (Fig. 3) . Therefore, these compounds were considered full agonists. ENL and 6OH-ENL showed markedly lower efficacies than DES and were considered partial agonists (Fig. 3 ). More interestingly, the daidzein metabolites 347-IF and 467-IF showed distinctively higher-fold induction than DES or E2 (Figs. 2 and 3). These high efficacies were observed at doses of 10 mM and higher only. These compounds resembled superagonists but with very weak potencies.
Next to the agonistic activity, the antagonistic activity on ER is important for the characterization of endocrine-active compounds. All phytoestrogens (Fig. 1) were tested for their potency to inhibit DES-induced, ER-mediated activity in IshikawahERa and Ishikawa-hERb. As expected, the partial agonists ENL and 6OH-ENL acted as partial antagonists (20-40% reduction of DES activity, data not shown). Distinct antagonistic activities were observed for RESV and ZEA only (Fig. 4 ). All other phytoestrogens tested did not inhibit ER activity at doses up to 100 mM (data not shown). RESV has been identified as a mixed ERa agonist/antagonist Bowers et al., 2000) . We analyzed in more detail its antagonistic properties with regard to ERa and ERb. In contrast to ZEA that showed dose-dependent antagonistic activity on ERa and ERb, RESV Transactivational potencies and efficacies of DES, E2, and phytoestrogens in Ishikawa cells stably expressing human ERa (Ishikawa-hERa) or ERb (Ishikawa-hERb). Transcriptional activity was measured on reporter vectors containing three copies of (A and B) the consensus ERE (3 3 ERE) or (C and D) the human C3 promoter. Relative potency was calculated by 100 * EC 50 (DES)/EC 50 (test compound) and is indicated next to each column. DES was set to 100. EC 50 values (ligand concentration yielding half-maximal activation) were derived by nonlinear curve-fitting from transactivation curves obtained in IshikawahERa or Ishikawa-hERb cells (e.g., Fig. 2 ) and are given as mean 6 standard deviation of at least three independent experiments. Please note (A and C) the logarithmic scale of EC 50 values. Relative efficacy was calculated by 100 * efficacy (DES)/efficacy (test compound). DES was set to 100. (B and D) Efficacies (maximum fold induction over control) were determined from transactivation curves obtained in Ishikawa-hERa or Ishikawa-hERb cells (e.g., Fig. 2 ) and are given as mean 6 standard deviation of at least three independent experiments. *EC 50 value could not be determined; therefore, the highest dose tested is given in parentheses.
18 displayed an inverted U-shaped dose response (Fig. 4) . At low doses, RESV increased the DES-induced activity of ERa and ERb, but at high doses it inhibited activity of ERa and ERb (Fig.  4) . We then compared the antiestrogenic potencies of RESV and ZEA with the pure antiestrogen ICI (Wakeling and Bowler, 1992) . The IC 50 values for the inhibition of DES-induced activity are shown in Table 2 . ZEA showed a higher antiestrogenic potency than RESV; both RESV and ZEA showed similar potencies on ERa and ERb in the mM range, whereas ICI was antiestrogenic at nM doses (Table 2) .
Phytoestrogens Exhibited a Distinct Enhancement and/or Repression of Coactivator Recruitment to ERa and ERb
Activation of the ER depends on the proper recruitment of coactivators that facilitate the transcription of ER target genes (Tremblay and Giguere, 2002) . Recruitment of coactivators may, therefore, also determine the ER subtype-specific activation by phytoestrogens . We analyzed the recruitment of two major coactivators, GRIP1 also known as TIF2 (Voegel et al., 1996) and SRC-1 (Onate et al., 1995) , that interact with ERa and ERb and are able to facilitate ER transactivation in HepG2 cells (Mueller et al., 2003a) . Firstly, we performed dose-response curves with the compounds tested in two-hybrid assays in human HepG2 cells. All agonists tested, DES, E2, ZEA, COUM, GEN, and RESV, induced a dosedependent increase in the recruitment of both GRIP1 and SRC-1 to ERa and ERb (data not shown). The daidzein metabolites 347-IF and 467-IF displayed distinct coactivator recruitment to ERa and ERb at doses of 10 mM and higher, which is in agreement with the transactivation data (Figs. 2 and 3 ). For comparison of the selected phytoestrogens, we chose the doses for each compound that elicited the maximum response in coactivator recruitment (Fig. 5) . ERa preferentially associated with GRIP1 compared to SRC-1 in the presence of the potent estrogens E2 and DES. ZEA, a potent ERa agonist (Fig. 3) , induced strong association of GRIP1 to ERa similar to E2 and DES (Fig. 5A) . ERa but not ERb showed preferential association with GRIP1 over SRC-1 in the presence of the ER agonists COUM, GEN, and RESV, whereas the superagonists 347-IF and 467-IF showed no differences and induced similar 2.8 6 0.4 nM RESV 33 6 11 mM 3 5 6 12 mM ZEA 8.1 6 4.3 mM 2.8 6 1.4 mM a Inhibition of transcriptional activity by test compounds was measured in the presence of 0.5 nM DES on the consensus ERE (3 3 ERE) reporter vector in Ishikawa-hERa and Ishikawa-hERb.
b IC 50 values (ligand concentration yielding 50% inhibition of DESinduced activity) were derived by nonlinear curve-fitting from transactivation curves obtained in Ishikawa-hERa or Ishikawa-hERb cells (e.g., Fig. 4 ) and are given as mean 6 standard deviation of at least three independent experiments. ESTROGENICITY OF PHYTOESTROGENS association of SRC-1 and GRIP1 to ERa and ERb (Fig. 5) . For ERb, no distinct preference for GRIP1 or SRC-1 was apparent (Fig. 5B) .
Since RESV and ZEA were antiestrogenic in Ishikawa-hERa and Ishikawa-hERb (Fig. 4 and Table 2), we analyzed whether RESV or ZEA were able to repress coactivator recruitment induced by DES (Figs. 6 and 7) . As positive control, we tested the pure ER antagonist ICI that completely repressed coactivator recruitment induced by DES (data not shown). RESV also repressed recruitment of either GRIP1 or SRC-1 to ERa and ERb at high doses (10-100 mM; Fig. 6 ). Recruitment of both GRIP1 and SRC-1 to ERa showed no distinct inverted U-shaped dose response when cells were treated with DES together with RESV (Fig. 6) . The characteristic inverted U-shaped dose 
FIG. 5.
Phytoestrogens showed distinct abilities to recruit coactivators to ERa and ERb. Mammalian two-hybrid assays were used to quantify the ligand-induced interaction of human ERa and ERb with the coactivators GRIP1 and SRC-1. For these experiments, constructs containing the GRIP1 and SRC-1 receptor interaction domains (NR-box) fused to the Gal4 transcription factor DNA-binding domain (pM-GRIP1 and pM-SRC-1) were used together with constructs containing either the human ERa or ERb cDNA fused in frame to the VP16 activation domain (pVP16-hERa and pVP16-hERb). HepG2 cells were transiently transfected with the 53-Gal4-TATALuc reporter, the pRL-CMV normalization plasmid, and either pM-GRIP1 (GRIP1, open columns) or pM-SRC-1 (SRC-1, solid columns) together with (A) pVP16-hERa or (B) pVP16-hERb. Following transfection, cells were treated with vehicle (control) or test compound at the indicated concentration. After 22 h, cells were harvested and dual luciferase assays were performed. Each value was normalized to the internal luciferase control. Shown is a representative experiment with each data point being the average with range of duplicate determinations. Experiments were performed three times with consistent results. Inhibition of coactivator recruitment to ER by resveratrol (RESV). Mammalian two-hybrid assays were used to quantify the interaction of human ERa with the coactivators GRIP1 and SRC-1 in the presence of RESV. For these experiments, constructs containing the GRIP1 and SRC-1 receptor interaction domains (NR-box) fused to the Gal4 transcription factor DNA-binding domain (pM-GRIP1 and pM-SRC-1) were used together with constructs containing either the human ERa or ERb cDNA fused in frame to the VP16 activation domain (pVP16-hERa or pVP16-hERb). HepG2 cells were transiently transfected with the 5 3 -Gal4-TATA-Luc reporter, the pRL-CMV normalization plasmid, and either pM-GRIP1 (GRIP1, open columns) or pM-SRC-1 (SRC-1, solid columns) together with (A) pVP16-hERa or (B) pVP16-hERb. Following transfection, cells were treated with vehicle (control) or 10 nM diethylstilbestrol (DES) and RESV as indicated for 22 h. After 22 h, cells were harvested and dual luciferase assays were performed. The dotted line indicates the relative value of the positive control DES (set to 100%). Each value was normalized to the internal luciferase control. Shown is a representative experiment with each data point being the average with range of duplicate determinations. Experiments were repeated three times with consistent results. 20 response, as observed in Figure 4 , was apparent for the recruitment of SRC-1 but not GRIP1 to ERb only (Fig. 6B) . ZEA reduced recruitment of GRIP1 to ERa and ERb in a dosedependent fashion (Fig. 7) , in agreement with the transactivation data (Fig. 4) . Interestingly, recruitment of SRC-1 to ERa and ERb was not consistently impaired by ZEA (Fig. 7) . These results indicated that phytoestrogens are able to alter the recruitment of coregulators depending on the type of coactivator and ER subtype.
DISCUSSION
Most phytoestrogens exert pleiotropic effects on cellular signaling and show some beneficial effects on estrogen-dependent diseases (Adlercreutz, 1995) . However, these compounds can also promote tumor growth (Hilakivi-Clarke et al., 1999a; Newbold et al., 2001 ) and cause developmentally adverse effects (Delclos et al., 2001; Jefferson and Newbold, 2000) . Although the beneficial effects, such as the prevention of mammary carcinomas by genistein in rodents (Murrill et al., 1996) , have been attributed to the antiestrogenic effects, experimental evidence suggests that estrogenic effects of isoflavones and potent estrogens during prepubertal development may prevent mammary tumors (Cotroneo et al., 2002; Grubbs et al., 1985; Hilakivi-Clarke et al., 1999b; Murrill et al., 1996) . However, these estrogenic effects are likely to turn into a detrimental response, i.e., tumor promotion, during later stages of development. In contrast, antiestrogenic compounds can prevent or reduce estrogen-dependent tumor growth independent of timing of exposure . Thus, these results warrant a cautious evaluation of the use of phytoestrogens to prevent estrogen-dependent diseases and require a thorough analysis of the estrogenic and antiestrogenic properties of these compounds.
In an attempt to provide a comprehensive analysis and potency comparison of the (anti-) estrogenicity of phytoestrogens, we evaluated several abundant phytoestrogens for ER binding, activation/inhibition, and coactivator recruitment in human cells. For this, we used a cell line with defined expression of either human ERa or ERb (Mueller et al., 2003a) . Since this cell line lacks activity to metabolize xenobiotics, we also analyzed some major human metabolites. The physiological effects of estrogens are mediated predominantly by ERa Mueller and Korach, 2001a) , whereas ERb may counteract ERa action (Hall and McDonnell, 1999; Liu et al., 2002) and has an important role at least in ovarian development . Therefore, it is crucial for the evaluation of the (anti)-estrogenicity of phytoestrogens to analyze both ERa and ERb. Kuiper and colleagues were the first ones to compare several xenoestrogens for ERa versus ERb binding and activity (Kuiper et al., 1998) . However, no study has yet compared the potencies and characteristics of various phytoestrogens and their metabolites for ERa and ERb activity in a comprehensive manner. Mammalian two-hybrid assays were used to quantify the interaction of human ERa with the coactivators GRIP1 and SRC-1 in the presence of ZEA. For these experiments, constructs containing the GRIP1 and SRC-1 receptor interaction domains (NR-box) fused to the Gal4 transcription factor DNAbinding domain (pM-GRIP1 and pM-SRC-1) were used together with constructs containing either the human ERa or ERb cDNA fused in frame to the VP16 activation domain (pVP16-hERa or pVP16-hERb). HepG2 cells were transiently transfected with the 5 3 -Gal4-TATA-Luc reporter, the pRL-CMV normalization plasmid, and either pM-GRIP1 (GRIP1, open columns) or pM-SRC-1 (SRC-1, solid columns) together with (A) pVP16-hERa or (B) pVP16-hERb. Following transfection, cells were treated with vehicle (control) or 10 nM diethylstilbestrol (DES) and ZEA as indicated for 22 h. After 22 h, cells were harvested and dual luciferase assays were performed. The dotted line indicates the relative value of the positive control DES (set to 100%). Each value was normalized to the internal luciferase control. Shown is a representative experiment with each data point being the average with range of duplicate determinations. Experiments were repeated three times with consistent results. Table 3 summarizes our results on the estrogenic characteristics of the phytoestrogens tested. In the former study, GEN and COUM displayed a preference for ERb (Kuiper et al., 1998) . We confirmed that GEN, COUM, and equol have a distinctively higher binding affinity but only slight preference for transactivation of ERb compared to ERa. However, the physiological relevance, if any, for this ERb propensity remains elusive. The potencies of these phytoestrogens were 10-to 100-fold less than that of DES. In contrast, ZEA was the most potent phytoestrogen tested and activated preferentially ERa. All other phytoestrogens tested including RESV and the daidzein and ENL metabolites were weak to very weak ER agonists (Table 3) . The daidzein metabolites 347-IF and 467-IF exhibited an interesting and rather surprising feature. Both isoflavones were very weak ER agonists, eliciting no activity up to a dose of 1 mM, but were superagonists compared to DES at doses of 10 to 100 mM. The pure antiestrogen ICI completely blocked 347-IF-and 467-IF-induced activity (data not shown), indicating that the measured ER superagonism is due to ligand-dependent activation.
ESTROGENICITY OF PHYTOESTROGENS
Since the expression of ER target genes depends on the promoter and ERE sequences (reviewed in Klinge, 2001) , we analyzed ER activity on a synthetic consensus ERE (3 3 ERE) and the promoter of the endometrial estrogen-responsive C3 gene (Norris et al., 1996) . A reporter with multiple copies of ERE, like the 3 3 ERE, enabled the detection of very weakly potent xenoestrogens that may lack measurable activity on natural, single EREs. Nevertheless, we had previously shown that imperfect single EREs might in fact increase estrogen-induced activity of ERa and ERb compared to the consensus ERE . Whether this observation can be extrapolated to an increased induction of target genes that contain imperfect EREs remains to be analyzed. In the present study, all tested phytoestrogens showed reduced potencies compared to DES and E2 on the C3 promoter; this is likely due to the lower sensitivity of the full-length C3 promoter compared to the 3 3 ERE reporter . ZEA was the most prominent phytoestrogen with regard to lower potency on the C3 promoter, an estrogen-responsive endometrial marker, for ERb, despite being the most potent phytoestrogen tested. Whether this ERE dependency for ZEA may result in tissue-specific effects has to be evaluated in vivo. Taken together, these results strengthened the notion that phytoestrogens are likely to exert tissue-specific effects. However, to provide more conclusive evidence for a potential tissue specificity of phytoestrogens, a broad panel of tissue-specific markers should be investigated (Cassidy, 1999) .
Beneficial effects on estrogen-related diseases are often attributed to antiestrogenic activities of phytoestrogens (Bingham et al., 1998) . Analysis of antagonistic activity on ERa and ERb revealed that only RESV and ZEA displayed apparent inhibitory properties on both ERa and ERb transactivation. The partial agonists ENL and 6OH-ENL were also partial antagonists in accordance with basic pharmacological principles. Bowers and colleagues reported that RESV showed slight antagonistic properties on ERa but not ERb depending on the ERE sequence (Bowers et al., 2000) . We observed an increase of DES-induced activity on the consensus ERE by both ERa and ERb at doses up to 10 mM for RESV. At 100 mM, RESV repressed activity of both ERa and ERb. The apparently contrasting results observed with ERb are likely due to the lower maximum dose of 50 mM tested in the former study and/or the use of different ERE sequences (Bowers et al., 2000) . The ERa antagonistic properties of RESV were confirmed in mammary tumor models as well as in Ishikawa cells with endogenous ERa expression . Taken together, the published reports and our data support that RESV has the potential to act as a mixed agonist/antagonist in an EREand dose-dependent fashion, and this may, next to its nonestrogenic effects (Dong, 2003) , account for RESV's beneficial effects. ZEA was a more potent antiestrogen than RESV and lacked any additive agonistic effects with DES on ERa and ERb, indicating its potential to act as a pure ER antagonist at high doses.
Recruitment of coactivators to ERa and ERb is a prerequisite for ER action, and ER coactivators are also important determinants for tissue-specific estrogen action, since coregulators show a tissue-specific expression profile (reviewed in Tremblay and Giguere, 2002) . ER ligands regulate recruitment of coactivators by inducing a distinct conformation of the ligand binding and activation domains of the ERs (Paige et al., 1999) . Thus, it is reasonable to assume that a conformational change induced by different phytoestrogens caused the observed distinct transactivation of ERa and ERb . We showed that all ER agonists tested enhanced recruitment of coactivators at doses similar to that which induced transactivation. This confirmed that coactivator recruitment is necessary for ER action and that a b Potent means more than 10% potency compared to DES; agonist means less than 10% but more than 1% potency compared to DES; weak means less than 1% but more than 0.1% potency compared to DES; very weak means less than 0.1% potency compared to DES. 22 two-hybrid coactivator assay could serve as surrogate marker for ER activation (Nishikawa et al., 1999) .
Previous studies analyzed coactivator recruitment to ERa and ERb in the presence of phytoestrogens using glutathione-S-transferase pull-down or yeast two-hybrid assays Nishikawa et al., 1999; Routledge et al., 2000) . These studies showed that ERb-selective phytoestrogens like genistein were more potent to recruit coactivators to ERb compared to ERa. We also observed maximum recruitment of coactivators to ERb at lower doses of GEN and COUM, albeit with lower efficacy, compared to ERa. All the rather potent phytoestrogens we studied enhanced preferentially recruitment of GRIP1 to ERa, confirming the report by Nishikawa and colleagues (1999) . This phytoestrogen-induced GRIP1 propensity of ERa was similar to that induced by E2, indicating that the molecular mechanism of ERa agonist activity of the phytoestrogens tested is comparable to potent estrogens. In contrast, the weakly potent superagonists 347-IF and 467-IF did not preferentially recruit one coactivator. For ERb, no distinct preference for one coactivator was apparent and the overall association was less pronounced than for ERa. This confirmed the generally observed lower efficacy of ERb compared to ERa regardless of the higher ERb affinity and potency of some phytoestrogens tested. The ER antagonists ZEA and RESV repressed GRIP1 association to ERa to a greater extent than for SRC-1, confirming their agonist profiles. Interestingly, RESV displayed the typical inverted U-shaped dose response for ERb antagonism for SRC-1 association but not for GRIP1. Also, GRIP1 association with ERb was diminished at low, agonistic doses of RESV. Taken together, these findings indicate that SRC-1 rather than GRIP1 may contribute to RESV's weak agonistic activity on ERb at lower doses.
The reported agonistic and antagonistic activity of the phytoestrogens we studied can aid in the evaluation of potential hazards or benefits of these compounds. Enterolactones are highly abundant in flaxseeds and lentils, food more common in a western diet, while isoflavones found in soy and tofu are generally considered part of an eastern diet (Cassidy et al., 2000) . Due to their abundance (Cassidy et al., 2000; Munro et al., 2003) and potencies, the soy-derived GEN, COUM, the daidzein metabolites equol and the superagonists 347-IF and 467-IF, RESV found mainly in grapes, and the mycotoxin ZEA seem to be relevant as far as potential risk/benefit of their (anti)-estrogenic effects. The isoflavones showed all pure ER agonistic activity. Thus, these compounds should be regarded as potentially estrogenic and, consequently, as potential endocrine disruptors that may cause elevated cell proliferation leading to estrogen-dependent tumor promotion (Allred et al., 2001; Cotroneo et al., 2002; Hilakivi-Clarke et al., 1999a; Newbold et al., 2001) and that may also induce adverse developmental effects (Delclos et al., 2001) . The beneficial effects associated with soy intake are likely due in part to non-ER-mediated effects as described above. But, with regard to the adverse and beneficial ER-mediated effects, the timing of exposure is important (Bouker and Hilakivi-Clarke, 2000; Cotroneo et al., 2002) . In contrast, RESV's very weak agonistic properties together with its antagonistic properties are likely to be major contributors to the beneficial effects attributed to RESV . ZEA might act as an endocrine disruptor at low doses, but its ER antagonistic activity at high doses might contribute to the observed reduction of mammary tumors (Hilakivi-Clarke et al., 1999b) . Next to the direct effects on ER activity that were analyzed in this study, phytoestrogens might also affect the formation of endogenous estrogens like 17b-estradiol. One well-characterized and potential target that regulates estradiol formation is aromatase, the enzyme that catalyzes the conversion of testosterone to estradiol. Indeed, indirect evidence for antiestrogenic effects due to inhibition of the formation of 17b-estradiol has been provided for biochanin A but not genistein at low doses (Almstrup et al., 2002) .
In conclusion, the risks and benefits of estrogenic or antiestrogenic effects depend highly on the target tissue as well as the timing and level of exposure. These latter two factors along with further research on the potential tissue-specific effects of phytoestrogens should aid in the assessment of the real risks and benefits of phytoestrogen-containing diets.
